229. 肺胞蛋白症（自己免疫性又は先天性） Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details
臨床試験数 : 44 / 薬物数 : 22 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03231033 (ClinicalTrials.gov) | August 17, 2017 | 19/6/2017 | Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis | First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis | Autoimmune Pulmonary Alveolar Proteinosis | Drug: Pioglitazone | Children's Hospital Medical Center, Cincinnati | NULL | Completed | 18 Years | 80 Years | All | 3 | Phase 1 | United States |